Monoclonal Antibodies to Disrupt Progression of Early Covid-19 Infection
Public Deposited- Creator
-
Cohen, M.S.
- Affiliation: School of Medicine
- Abstract
- By the end of 2020, more than 19 million Americans had received the diagnosis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Although a substantial proportion of these infections remained asymptomatic, complications of coronavirus disease 2019 (Covid-19) had led to more than 330,000 deaths in the United States. During the past year, a remarkable effort has been devoted to the development of vaccines to prevent Covid-19 and to reduce morbidity and mortality among those who are infected. Equally important is the development of treatments that can prevent the progression of Covid-19 from the inception of infection.
- Date of publication
- 2021
- Keyword
- placebo
- disease course
- Antibodies, Neutralizing
- high risk population
- virus antibody
- bamlanivimab
- neutralizing antibody
- hospitalization
- casirivimab plus imdevimab
- drug efficacy
- disease burden
- drug research
- reverse transcription polymerase chain reaction
- virus RNA
- nonhuman
- Outpatients
- monoclonal antibody
- Editorial
- Antibodies, Viral
- health care system
- virus load
- drug indication
- nasopharyngeal swab
- early intervention
- regn cov2
- Antibodies, Monoclonal
- virus shedding
- SARS-CoV-2
- COVID-19
- etesevimab
- coronavirus spike glycoprotein
- priority journal
- coronavirus disease 2019
- human
- outpatient
- Humans
- DOI
- Identifier
- Resource type
- Article
- Rights statement
- In Copyright
- Journal title
- New England Journal of Medicine
- Journal volume
- 384
- Journal issue
- 3
- Page start
- 289
- Page end
- 291
- Language
- English
- ISSN
- 0028-4793
- Publisher
- Massachussetts Medical Society
Relations
- Parents:
- In Collection:
This work has no parents.
Items
| Thumbnail | Title | Date Uploaded | Visibility | Actions |
|---|---|---|---|---|
|
|
nejme2034495.pdf | 2023-11-16 | Public | Download |